← Back to Screener
Oragenics Inc. (OGEN)
Price$0.71
Favorite Metrics
Price vs S&P 500 (26W)-53.75%
Price vs S&P 500 (4W)-13.65%
Market Capitalization$3.10M
All Metrics
Book Value / Share (Quarterly)$1.94
P/TBV (Annual)0.71x
Cash Flow / Share (Quarterly)$-2.16
Price vs S&P 500 (YTD)-12.85%
Gross Margin (TTM)61.29%
Net Profit Margin (TTM)-19750.00%
EPS (TTM)$-5.61
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-5.61
EPS (Annual)$-4.56
ROI (Annual)-115.67%
Gross Margin (Annual)60.64%
Net Profit Margin (5Y Avg)-17097.31%
Cash / Share (Quarterly)$1.97
ROA (Last FY)-97.76%
EBITD / Share (TTM)$-3.37
ROE (5Y Avg)-219.39%
Operating Margin (TTM)-20250.00%
Cash Flow / Share (Annual)$-2.16
P/B Ratio0.37x
P/B Ratio (Quarterly)0.39x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)-26.80x
Net Interest Coverage (TTM)-15.18x
ROA (TTM)-91.83%
EPS Incl Extra (Annual)$-4.56
Current Ratio (Annual)5.64x
Quick Ratio (Quarterly)4.73x
3-Month Avg Trading Volume0.39M
52-Week Price Return-86.66%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.53
P/S Ratio (Annual)82.34x
Asset Turnover (Annual)0.01x
52-Week High$9.60
Operating Margin (5Y Avg)-17266.36%
EPS Excl Extra (Annual)$-4.56
Tangible BV CAGR (5Y)15.55%
26-Week Price Return-45.00%
Quick Ratio (Annual)4.73x
13-Week Price Return-22.28%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)5.64x
Enterprise Value$-1.072
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-38.69%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)-54862.52%
Cash / Share (Annual)$1.97
3-Month Return Std Dev97.64%
Gross Margin (5Y Avg)48.54%
Net Income / Employee (TTM)$-3
ROE (Last FY)-118.85%
Net Interest Coverage (Annual)-7.12x
EPS Basic Excl Extra (Annual)$-4.56
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-5.61
Receivables Turnover (Annual)0.00x
ROI (TTM)-57.15%
P/S Ratio (TTM)77.51x
Pretax Margin (5Y Avg)-17097.31%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.43
Price vs S&P 500 (52W)-121.76%
Year-to-Date Return-8.71%
5-Day Price Return4.98%
EPS Normalized (Annual)$-4.56
ROA (5Y Avg)-276.76%
Net Profit Margin (Annual)-54862.52%
Month-to-Date Return27.66%
Cash Flow / Share (TTM)$-4.69
EBITD / Share (Annual)$-4.34
Operating Margin (Annual)-55524.33%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-206.03%
LT Debt / Equity (Quarterly)2.38x
EPS Basic Excl Extra (TTM)$-5.61
P/TBV (Quarterly)1.42x
P/B Ratio (Annual)0.39x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-19750.00%
Book Value / Share (Annual)$1.94
Price vs S&P 500 (13W)-25.15%
Beta1.44x
P/FCF (Annual)25.84x
Revenue / Share (TTM)$0.00
ROE (TTM)-59.11%
52-Week Low$0.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OGENOragenics Inc. | 77.51x | — | 61.29% | — | $0.71 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Oragenics Inc develops nasal-delivery pharmaceutical treatments for neurology and infectious diseases. The company's lead candidate, ONP-002, is a synthetic neurosteroid designed to cross the blood-brain barrier and rapidly reduce inflammation, swelling, and oxidative stress. ONP-002 is being developed to treat concussions by restoring proper blood flow.